FOLH1 and prostate cancer: The anti-prostate specific membrane antigen (PSMA) × anti-CD3 tetravalent, bispecific ADAPTIRTM TRBA molecule MOR209 (also called ES414) [164] is currently being tested in Phase 1 clinical trials [213] for the potential treatment of prostate cancer.